Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology

Pansa, Camila Cristiane; Molica, Letícia Ramos; Moraes, Karen C. M.

doi:10.1080/00365521.2022.2148835

Cited by 1 publication

(2 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gene expression profiling and genome-wide association studies have led to the identification of gene polymorphisms and novel disease pathways that have enriched our understanding of the genetic basis of the disease and may prove to be potential biomarkers of NAFLD progression as well as possible targets of future therapy. [60][61][62][63][64][65] In addition to conventional genetics, epigenetics, an inheritable phenomenon that affects gene expression without changing the DNA order, provides a new perspective on the pathogenesis of NAFLD. The epigenetic changes take place at the transcriptional level and provide a phenotypic connection between the host and the environment.…”

Section: Pathogenesismentioning

confidence: 99%

“…The PPARA gene codes for a protein that is involved in regulating lipid metabolism in the liver and the variants of this gene have been associated with an increased risk of developing NAFLD and its progression to advanced liver disease. [60][61][62][63][64][65] More recently, epigenetic factors have also been found to play an important role in the pathogenesis of NAFLD.…”

Section: Pathogenesismentioning

confidence: 99%

See 1 more Smart Citation

Non-alcoholic fatty liver disease: An emerging epidemic of global importance

Mubarak

2023

Gastroenterol Funct Med

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD), a condition that affects 30% of the world’s population, is one of the leading causes of chronic liver disease (CLD) and liver transplantation. Although exact data are not available in many developing countries, its prevalence is increasing at alarming rates in many studies from these countries. The rising prevalence of NAFLD has paralleled the increasing rates of obesity and metabolic syndrome. Hence, more recently, it has been renamed metabolic dysfunction-associated fatty liver disease (MAFLD). Since several studies have demonstrated an association between NAFLD and an increased risk of cardiovascular events, it has been proposed that NAFLD may be an independent risk factor for atherosclerosis. However, the data is conflicting in this regard and more studies are needed. In this review, we discussed the epidemiology, risk factors, clinical presentation, diagnosis, classification, and complications of NAFLD to help increase awareness among the medical community of this looming epidemic of metabolic liver injury.

show abstract